Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm Phase II Trial of Trastuzumab Deruxtecan in Patients With Gastrooesophageal Adenocarcinoma Cancer Who Are ctDNA and HER2 Positive

NCT05965479 is registered in ClinicalTrials.gov with University of Southampton as lead sponsor.

NCT NCT05965479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05965479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm Phase II Trial of Trastuzumab Deruxtecan in Patients With Gastrooesophageal Adenocarcinoma Cancer Who Are ctDNA and HER2 Positive
Lead sponsor
University of Southampton
Phase
Phase 2
Overall status
Recruiting
Start date
April 10, 2024
Completion date
April 30, 2028
Enrollment
25 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

gastrooesophageal cancer